1 month Regeneron Pharmaceuticals (NASDAQ:REGN) Receives “Neutral” Rating from Cantor FitzgeraldMarketBeat
Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday.
Nasdaq 100 · Pharmaceuticals · Regeneron Pharma (REGN) · Science
X